Mangalam Drugs Reports Decline in Sales and Profitability Amid Operational Challenges in June 2025
Mangalam Drugs and Organics has reported financial results for the quarter ending June 2025, highlighting operational challenges. Net sales were Rs 57.35 crore, significantly lower than previous quarters. Profit before tax fell to Rs -13.00 crore, and the operating profit margin reached -7.79%, indicating declining profitability and efficiency.
Mangalam Drugs and Organics has reported its financial results for the quarter ending June 2025, revealing significant challenges within its operations. The company's net sales for the quarter stood at Rs 57.35 crore, reflecting a notable decline compared to the average of Rs 79.56 crore over the previous four quarters. This downturn indicates a concerning trend in sales performance.Additionally, the profit before tax less other income (PBT) has shown a drastic shift, recorded at Rs -13.00 crore, which is substantially lower than the average PBT of Rs 1.07 crore from the last four quarters. This suggests a significant deterioration in profitability.
The operating profit margin has also reached its lowest point in five quarters at -7.79%, indicating challenges in operational efficiency. Furthermore, the earnings per share (EPS) have declined to Rs -8.72, highlighting a reduction in profitability for shareholders.
In light of these developments, Mangalam Drugs has experienced an adjustment in its evaluation, with its score reflecting these adverse financial trends.
Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
